TY - JOUR
T1 - Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non–Small-Cell Lung Cancer
AU - Gregorc, V.
AU - Mazzarella, L.
AU - Lazzari, C.
AU - Graziano, P.
AU - Vigneri, P.
AU - Genova, C.
AU - Toschi, L.
AU - Ciliberto, G.
AU - Bonanno, L.
AU - Delmonte, A.
AU - Bucci, G.
AU - Rossi, A.
AU - Motta, G.
AU - Coco, S.
AU - Marinello, A.
AU - Buglioni, S.
AU - Cangi, M. G.
AU - Di, Micco C.
AU - Bandiera, A.
AU - Bonfiglio, S.
AU - Pecciarini, L.
AU - Guida, A.
AU - Ceol, A.
AU - Frige', G.
AU - De Maria Marchiano, Ruggero
AU - Pelicci, P. G.
PY - 2021
Y1 - 2021
N2 - Background: The deeper knowledge of non–small-cell lung cancer (NSCLC) biology and the discovery of driver molecular alterations have opened the era of precision medicine in lung oncology, thus significantly revolutionizing the diagnostic and therapeutic approach to NSCLC. In Italy, however, molecular assessment remains heterogeneous across the country, and numbers of patients accessing personalized treatments remain relatively low. Nationwide programs have demonstrated that the creation of consortia represent a successful strategy to increase the number of patients with a molecular classification. Patients and Methods: The Alliance Against Cancer (ACC), a network of 25 Italian Research Institutes, has developed a targeted sequencing panel for the detection of genomic alterations in 182 genes in patients with a diagnosis of NSCLC (ACC lung panel). One thousand metastatic NSCLC patients will be enrolled onto a prospective trial designed to measure the sensitivity and specificity of the ACC lung panel as a tool for molecular screening compared to standard methods. Results and Conclusion: The ongoing trial is part of a nationwide strategy of ACC to develop infrastructures and improve competences to make the Italian research institutes independent for genomic profiling of cancer patients.
AB - Background: The deeper knowledge of non–small-cell lung cancer (NSCLC) biology and the discovery of driver molecular alterations have opened the era of precision medicine in lung oncology, thus significantly revolutionizing the diagnostic and therapeutic approach to NSCLC. In Italy, however, molecular assessment remains heterogeneous across the country, and numbers of patients accessing personalized treatments remain relatively low. Nationwide programs have demonstrated that the creation of consortia represent a successful strategy to increase the number of patients with a molecular classification. Patients and Methods: The Alliance Against Cancer (ACC), a network of 25 Italian Research Institutes, has developed a targeted sequencing panel for the detection of genomic alterations in 182 genes in patients with a diagnosis of NSCLC (ACC lung panel). One thousand metastatic NSCLC patients will be enrolled onto a prospective trial designed to measure the sensitivity and specificity of the ACC lung panel as a tool for molecular screening compared to standard methods. Results and Conclusion: The ongoing trial is part of a nationwide strategy of ACC to develop infrastructures and improve competences to make the Italian research institutes independent for genomic profiling of cancer patients.
KW - Bioinformatics
KW - Molecular tumor board
KW - NSCLC
KW - Next-generation sequencing
KW - Personalized therapy
KW - Bioinformatics
KW - Molecular tumor board
KW - NSCLC
KW - Next-generation sequencing
KW - Personalized therapy
UR - https://publicatt.unicatt.it/handle/10807/183048
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85101614128&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85101614128&origin=inward
U2 - 10.1016/j.cllc.2020.12.007
DO - 10.1016/j.cllc.2020.12.007
M3 - Article
SN - 1525-7304
VL - 22
SP - e637-e641
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 4
ER -
